Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy

J Crohns Colitis. 2021 Sep 25;15(9):1431-1442. doi: 10.1093/ecco-jcc/jjab050.

Bram Verstockt 1 2, Nurulamin M Noor 3 4, Urko M Marigorta 5 6, Polychronis Pavlidis 7 8, Parakkal Deepak 9, Ryan C Ungaro 10, Scientific Workshop Steering Committee


Author information


  • Scientific Workshop Steering Committee

Claudio Fiocchi, Joana Torres, Michael Scharl


  • 1University Hospitals Leuven Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
  • 2KU Leuven Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders [TARGID], Leuven, Belgium.
  • 3Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK.
  • 4Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • 5Integrative Genomics Lab, Center for Cooperative Research in Biosciences [CIC bioGUNE], Basque Research and Technology Alliance [BRTA], Derio, Spain.
  • 6IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
  • 7Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • 8School of Immunology and Microbial Sciences, King's College London, London, UK.
  • 9Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St Louis, MO, USA.
  • 10Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.


Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.